Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high-risk or node-positive prostate cancer: ENZARAD (ANZUP 1303)

Autor:	Paul L. Nguyen, Simon Hughes, Andrew J. Martin, Vittorio Marchesin, Howard Chan, Martin R. Stockler, Scott Williams, Sonia Yip, Xanthi Coskinas, Nicola Jane Lawrence, Emily Tu, Wendy Hague, Olwyn Deignan, Christopher Sweeney, Ray McDermott, Ian D. Davis
Rok vydání:	2016
Předmět:	Oncology Cancer Research medicine.medical_specialty Standard of care business.industry medicine.medical_treatment 030232 urology & nephrology medicine.disease Surgery Androgen deprivation therapy Radiation therapy 03 medical and health sciences Prostate cancer chemistry.chemical_compound 0302 clinical medicine chemistry 030220 oncology & carcinogenesis Internal medicine Medicine Enzalutamide business Lhrh analog Adjuvant hormones hormone substitutes and hormone antagonists
Zdroj:	Journal of Clinical Oncology. 34:TPS5086-TPS5086
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2016.34.15_suppl.tps5086
Popis:	TPS5086Background: Adjuvant ADT with an LHRH analog (LHRHA) given before during and after radiotherapy (RT) is standard of care for high risk localised prostate cancer (PC). Enzalutamide is more ef...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c98d4ae497d26d3b0c4f14dd1e963c0e https://doi.org/10.1200/jco.2016.34.15_suppl.tps5086 Zobrazit plný text záznamu